David Hung Vu

Array ( [id] => 20438683 [patent_doc_number] => 12509510 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => IL31-binding polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 19/187342 [patent_app_country] => US [patent_app_date] => 2025-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 9 [patent_no_of_words] => 55460 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19187342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389924 [patent_doc_number] => 20230158142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => BLOCKADE OF IFN SIGNALING DURING CANCER VACCINATION [patent_app_type] => utility [patent_app_number] => 17/990480 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391402 [patent_doc_number] => 20230159620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => COMPOSITIONS AND METHODS OF TREATMENT FOR VASCULAR DISEASES AND THROMBOSIS [patent_app_type] => utility [patent_app_number] => 17/978128 [patent_app_country] => US [patent_app_date] => 2022-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40546 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17978128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18338805 [patent_doc_number] => 20230130754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => SURFACE-MODIFIED EXOSOMES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/050195 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19875 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691067 [patent_doc_number] => 20230321268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => CONJUGATES ENHANCING TOTAL CELLULAR ACCUMULATION [patent_app_type] => utility [patent_app_number] => 18/046718 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18170465 [patent_doc_number] => 20230037076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => CHIMERIC CHLOROTOXIN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/864935 [patent_app_country] => US [patent_app_date] => 2022-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792123 [patent_doc_number] => 20220251214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Bispecific Antibodies for Activation of Immune Cells [patent_app_type] => utility [patent_app_number] => 17/723084 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17723084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776574 [patent_doc_number] => 20220242923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => COLD-SHOCK PROTEIN SCAFFOLD FOR ENGINEERING NON-ANTIBODY BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 17/589049 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17589049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749654 [patent_doc_number] => 20220227858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => CONTROLLING OF IMMUNE ACTIVATION BY SOLUBLE CLEVER-1 [patent_app_type] => utility [patent_app_number] => 17/577132 [patent_app_country] => US [patent_app_date] => 2022-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17577132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17577032 [patent_doc_number] => 20220133887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => ANTI-CD40 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/573730 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414332 [patent_doc_number] => 20220049236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => COMPOSITIONS COMPRISING THE PROPEPTIDE OF LYSYL OXIDASE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/515591 [patent_app_country] => US [patent_app_date] => 2021-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17515591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370017 [patent_doc_number] => 20220025069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING LIPOCALIN MUTEINS [patent_app_type] => utility [patent_app_number] => 17/498515 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314837 [patent_doc_number] => 20210403885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/475810 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20386590 [patent_doc_number] => 12486307 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Caustic stable chromatography ligands [patent_app_type] => utility [patent_app_number] => 17/388090 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 10 [patent_no_of_words] => 8684 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468879 [patent_doc_number] => 20230203162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => MULTISPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/000141 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18239822 [patent_doc_number] => 20230072133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => A BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/800197 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18948 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18238028 [patent_doc_number] => 20230070339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => LILRB3 ANTIBODY MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/799240 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14513 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067287 [patent_doc_number] => 20210269502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 17/165119 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18123971 [patent_doc_number] => 20230009582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => ANTI-SIGLEC-9 ANTIBODY MOLECULES [patent_app_type] => utility [patent_app_number] => 17/776980 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725885 [patent_doc_number] => 20230340122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => COMBINED INHIBITION OF PD-1, TGFB AND TIGIT FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/771227 [patent_app_country] => US [patent_app_date] => 2020-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771227 [rel_patent_id] =>[rel_patent_doc_number] =>)